¿Quién es inmune? ¿Inmunidad de rebaño o vacuna? | 30 ABR 20

Lo que los responsables sanitarios deben saber sobre la inmunidad protectora COVID-19

No hay certeza en cuanto a los correlatos inmunológicos de la protección antiviral o la proporción de la población que debe alcanzarlos, lo que hace imposible identificar un punto cuando se ha alcanzado este nivel de inmunidad.
39
24
Autor/a: Daniel M Altmann, Daniel C Douek, Rosemary J Boyton Fuente: The Lancet DOI:https://doi.org/10.1016/S0140-6736(20)30985-5 What policy makers need to know about COVID-19 protective immunity
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas
  1. Studdert DM Hall MA. Disease control, civil liberties, and mass testing—calibrating restrictions during the COVID-19 pandemic. N Engl J Med. 2020; (published online April) DOI:10.1056/NEJMp2007637
  2. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020; 64: e00399-e00420
  3. Amanat F Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020; 52: 583-589
  4. Thanh Le T Andreadakis Z Kumar A et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; (published online April 9.) DOI:10.1038/d41573-020-00073-5
  5. Adams ER Anand R Andersson M et al. Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. bioRxiv. 2020; (published online April 20.) (preprint) https://doi.org/10.1101/2020.04.15.20066407
  6. Plotkin SA. Vaccination against the major infectious diseases. CR Acad Sci III. 1999; 322: 943-951
  7. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001; 20: 63-75
  8. Tan W Lu Y Zhang J et al. Viral kinetics and antibody responses in patients with COVID-1 MedRxiv. 2020; (published online March 26.) (preprint)  https://doi.org/10.1101/2020.03.24.20042382
  9. Stanley DA Honko AN Asiedu C et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014; 20: 1126-1129
  10. Li CK Wu H Yan H et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008; 181: 5490-5500
  11. Temperton NJ Chan PK Simmons G et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis. 2005; 11: 411-416
  12. Choe PG Perera RAPM Park WB et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017; 23: 1079-1084
  13. Channappanavar R Zhao J Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014; 59: 118-128
  14. Department of Health and Social Care, UK Government. Government begins large-scale virus infection and antibody test study. https://www.gov.uk/government/news/government-begins-large-scale-virus-infection-and-antibody-test-study
  15. Anderson RM May RM. Vaccination and herd immunity to infectious diseases. Nature. 1985; 318: 323-329
  16. Li Q Guan X Wu P et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382: 1199-1207
  17. Guerra FM Bolotin S Lim G et al. The basic reproduction number (RO) of measles: a systematic review. Lancet Infect Dis. 2017; 17: e420-e428
  18. Wu F Wang A Liu M et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. bioRxiv. 2020; (published online April 20.) https://doi.org/10.1101/2020.03.30.20047365
  19. Feldmann M Maini RN Woody JN et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020; (published online April 9.) https://doi.org/10.1016/S0140-6736(20)30858-8
 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2020